Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer

被引:20
作者
Azais, Henri [1 ,2 ]
Vignion-Dewalle, Anne-Sophie [2 ]
Carrier, Marine [1 ]
Augustin, Jeremy [3 ]
Da Maia, Elisabeth [3 ]
Penel, Alix [4 ]
Belghiti, Jeremie [1 ]
Nikpayam, Marianne [1 ]
Gonthier, Clementine [1 ]
Ziane, Laurine [2 ]
Mordon, Serge [2 ]
Collinet, Pierre [2 ,5 ]
Canlorbe, Geoffroy [1 ,6 ,7 ]
Uzan, Catherine [1 ,6 ,7 ]
机构
[1] Pitie Salpetriere Univ Hosp, AP HP, Dept Gynecol & Breast Surg & Oncol, F-75013 Paris, France
[2] Univ Lille, CHU Lille, INSERM, U1189 ONCO THAI Laser Assisted Therapy & Immunoth, F-59000 Lille, France
[3] Hop La Pitie Salpetriere, AP HP, Dept Pathol, F-75013 Paris, France
[4] Hop La Pitie Salpetriere, AP HP, Ctr Pharmacoepidemiol, CEPHEPI, F-75013 Paris, France
[5] CHRU Lille, Jeanne de Flandre Hosp, Dept Gynecol, F-59000 Lille, France
[6] Sorbonne Univ, Ctr Rech St Antoine CRSA, INSERM, UMR S 938,Canc Biol & Therapeut, F-75020 Paris, France
[7] Sorbonne Univ, Inst Univ Cancerol IUC, F-75013 Paris, France
关键词
epithelial ovarian cancer; peritoneal carcinomatosis; cytoreductive surgery; gynecologic oncology; PERIOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; SURVIVAL; LAPAROTOMY; CARCINOMA; IMPACT; ERA;
D O I
10.3390/jcm10010041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Epithelial ovarian cancers (EOC) are usually diagnosed at an advanced stage and managed by complete macroscopic cytoreductive surgery (CRS) and systemic chemotherapy. Peritoneal recurrence occurs in 60% of patients and may be due to microscopic peritoneal metastases (mPM) which are neither eradicated by surgery nor controlled by systemic chemotherapy. The aim of this study was to assess and quantify the prevalence of residual mPM after complete macroscopic CRS in patients with advanced high-grade serous ovarian cancer (HGSOC). Methods: A prospective study conducted between 1 June 2018 and 10 July 2019 in a single referent center accredited by the European Society of Gynecological Oncology for advanced EOC management. Consecutive patients presenting with advanced HGSOC and eligible for complete macroscopic CRS were included. Up to 13 peritoneal biopsies were taken from macroscopically healthy peritoneum at the end of CRS and examined for the presence of mPM. A mathematical model was designed to determine the probability of presenting at least one mPM after CRS. Results: 26 patients were included and 26.9% presented mPM. There were no differences in characteristics between patients with or without identified mPM. After mathematical analysis, the probability that mPM remained after complete macroscopic CRS in patients with EOC was 98.14%. Conclusion: Microscopic PM is systematically present after complete macroscopic CRS for EOC and could be a relevant therapeutic target. Adjuvant locoregional strategies to conventional surgery may improve survival by achieving microscopic CRS.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 42 条
[1]   Surgical cytoreduction for recurrent epithelial ovarian cancer [J].
Al Rawahi, Thuria ;
Lopes, Alberto D. ;
Bristow, Robert E. ;
Bryant, Andrew ;
Elattar, Ahmed ;
Chattopadhyay, Supratik ;
Galaal, Khadra .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02)
[2]   Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas [J].
Albanese, Alfonso M. ;
Albanese, Eduardo F. ;
Mino, Jorge H. ;
Gomez, Elena ;
Gomez, Marta ;
Zandomeni, Marcos ;
Merlo, Alicia B. .
SURGICAL AND RADIOLOGIC ANATOMY, 2009, 31 (05) :369-377
[3]   Ovarian Cancer Sites of Recurrence [J].
Amate, Pascale ;
Huchon, Cyrille ;
Dessapt, Anne Lucie ;
Bensaid, Cherazade ;
Medioni, Jacques ;
Belda, Marie-Aude Le Frere ;
Bats, Anne-Sophie ;
Lecuru, Fabrice R. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (09) :1590-1596
[4]   Occult metastasis in early ovarian cancers: Risk factors and associated prognosis [J].
Ayhan, Ali ;
Gultekin, Murat ;
Celik, Nilufer Yigit ;
Dursun, Polat ;
Taskiran, Cagatay ;
Aksan, Guldeniz ;
Yuce, Kunter .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 196 (01) :81-83
[5]  
Azais H., 2019, WIPO Patent, Patent No. [WO2019016397 (A1), 2019016397]
[6]   Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge [J].
Azais, Henri ;
Estevez, Juan Pablo ;
Foucher, Perine ;
Kerbage, Yohan ;
Mordon, Serge ;
Collinet, Pierre .
SURGICAL ONCOLOGY-OXFORD, 2017, 26 (01) :46-52
[7]   Targeted approaches and innovative illumination solutions: A new era for photodynamic therapy applications in gynecologic oncology? [J].
Azais, Henri ;
Betrouni, Nacim ;
Mordon, Serge ;
Collinet, Pierre .
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2016, 13 :128-129
[8]   Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties [J].
Baydoun, Martha ;
Morales, Olivier ;
Frochot, Celine ;
Ludovic, Colombeau ;
Leroux, Bertrand ;
Thecua, Elise ;
Ziane, Laurine ;
Grabarz, Anne ;
Kumar, Abhishek ;
de Schutter, Clementine ;
Collinet, Pierre ;
Azais, Henri ;
Mordon, Serge ;
Delhem, Nadira .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
[9]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[10]   Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis [J].
Chang, Suk-Joon ;
Hodeib, Melissa ;
Chang, Jenny ;
Bristow, Robert E. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (03) :493-498